Abstract: Humanized models often lack accuracy and translatability regarding TME composition and tumor plasticity. This talk will present a humanized model in which human immune cell recruitment and activation in the TME is dependent on tumor type and burden. The presence of human myeloid and lymphoid cells allows assessment of the efficacy and safety of immunotherapies designed to reprogram TME composition. Alternatively, the assessment of therapies such as ADC and those inducing ADCC could be studied in a model expressing humanized FcγR, which, in contrast to humanized mice, shows a fully functional crosstalk between tumor, immune and stromal cells.
#3126: Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice
#3230: Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies
#5244: Assessment of γδT-cell therapies in genO-BRGSF-HIS mice
#7273: genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies
在疾病研究的征程中，每一次突破都离不开全球科研力量的汇聚与协作。AACR 2025 不仅是一场学术盛会，更是癌症研究领域创新与突破的前沿阵地。我们期待与您在芝加哥相聚，共同见证癌症研究的最新进展，携手探索未来的无限可能！
END
关于基锘威生物
genOway，全球知名的动物模型供应商，1999年创立于法国，立足模型原研，并拥有全球独家CRISPR/Cas9基础专利组合(Sigma-Aldrich (Merck)、Berkeley、Broad)许可证，在转基因小鼠、大鼠及细胞模型的研发上取得了显著成果，目前已与全球TOP20药企中的17家、500多家工业及学术机构建立合作。
2023年在中国成立中法合资公司——上海基锘威生物科技有限公司，标志着其全球化战略的重要布局。上海基锘威已建立完善的本地化生产设施，并同步建设继欧美之外的又一大全球化研发平台。这一举措可保障客户获得高品质动物模型的同时降低研发成本，同时大幅缩短中国及其他亚太地区的供货周期，确保客户及时获得所需模型及应用方案，共同推动医药科研领域的创新与发展。
更多信息可进官网查询：www.genoway-sh.com
